STAAR Surgical (STAA)

• Market cap: $831M
• 1 day: 0.12%
• 5 days: 3.88%
• 1 month: -26.68%
• 3 months: -36.65%
• 6 months: -52.72%
• Year to date: -30.00%
• 1 year: -44.49%
• 5 years: -51.38%
• 10 years: 164.42%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

Employees: 1,115

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

0.17% more ownership

Funds ownership: 98.0% [Q3] → 98.17% (+0.17%) [Q4]

3% less repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 75

9% less funds holding

Funds holding: 232 [Q3] → 210 (-22) [Q4]

34% less capital invested

Capital invested by funds: $1.79B [Q3] → $1.18B (-$615M) [Q4]

38% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 48

42% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $4.12M

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 5% downside
• Avg. target: $20 20% upside
• High target: $28 66% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Canaccord Genuity Jon Young 71% 1-year accuracy 5 / 7 met price target	1% upside $17	Hold Maintained	13 Feb 2025
Stifel Thomas Stephan 44% 1-year accuracy 8 / 18 met price target	19% upside $20	Buy Maintained	12 Feb 2025
Stephens & Co. Mason Carrico 40% 1-year accuracy 8 / 20 met price target	66% upside $28	Equal-Weight Reiterated	12 Feb 2025
Piper Sandler Matt O'Brien 64% 1-year accuracy 35 / 55 met price target	5% downside $16	Neutral Maintained	12 Feb 2025